Novel mechanism of crizotinib resistance in a ROS1+ NSCLC patient
Monday, April 11, 2016 - 14:41
in Health & Medicine
Molecular analysis of a tumor biopsy from a proto-oncogene 1 receptor tyrosine kinase positive (ROS1+) patient with acquired crizotinib resistance revealed a novel mutation in the v-kit Hardy Zuckerman 4 feline sarcoma viral oncogene homolog receptor tyrosine kinase (KIT) that can potentially be targeted by KIT inhibitors.